Audentes Signs an Exclusive License Agreement with Nationwide Children’s Hospital (NCH) for the Expansion of its AAV Technology and Pipeline

 Audentes Signs an Exclusive License Agreement with Nationwide Children’s Hospital (NCH) for the Expansion of its AAV Technology and Pipeline

Audentes Signs an Exclusive License Agreement with Nationwide Children’s Hospital (NCH) for the Expansion of its AAV Technology and Pipeline

Shots:

  • Audentes and NCH enter into a license agreement to develop AT702 designed to induce exon 2 skipping in DMD patients with exon 2 duplications and mutations in exons 1-5 in the dystrophin gene, with an expected initiation of P-I/II study in Q4’19
  • The partners are also evaluating vectorized RNA knockdown & exon skipping for myotonic dystrophy type 1 (DM1) with an expected IND filling for AT466 in 2020. AT702 is AVV-antisense candidate targeted for patients with DMD
  • Apart from the above collaboration, Audentes is conducting preclinical studies for AT751 and AT753 for DMD patients with genotypes amenable to exon 51 and 53 skipping

Click here to read full press release/ article | Ref: Audentes | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post